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Abstract
Background: Dystonia, cerebellar atrophy, and cardiomyopathy constitute a rare association.
Methods: We used homozygosity mapping and whole exome sequencing to determine the mutation, western
blot and immunolabelling on cultured fibroblasts to demonstrate the lower expression and the mislocalization of
the protein.
Results: We report on a boy born from consanguineous healthy parents, who presented at three years of age
with rapidly progressing dystonia, progressive cerebellar atrophy, and dilated cardiomyopathy. We identified regions
of homozygosity and performed whole exome sequencing that revealed a homozygous missense mutation in
TOR1AIP1. The mutation, absent in controls, results in a change of a highly conserved glutamic acid to alanine.
TOR1AIP1 encodes lamina-associated polypeptide 1 (LAP1), a transmembrane protein ubiquitously expressed in
the inner nuclear membrane. LAP1 interacts with torsinA, the protein mutated in DYT1-dystonia. In vitro studies in
fibroblasts of the patient revealed reduced expression of LAP1 and its mislocalization and aggregation in the
endoplasmic reticulum as underlying pathogenic mechanisms.
Conclusions and relevance: The pathogenic role of TOR1AIP1 mutation is supported by a) the involvement of a
highly conserved amino acid, b) the absence of the mutation in controls, c) the functional interaction of LAP1 with
torsinA, and d) mislocalization of LAP1 in patient cells. Of note, cardiomyopathy has been reported in LAP1-null
mice and in patients with the TOR1AIP1 nonsense mutation. Other cases will help delineate the clinical spectrum of
LAP1-related mutations.
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Background
Dystonia, cerebellar atrophy and cardiomyopathy con-
stitute a very rare association, observed in rare mito-
chondrial disease and organic acidemia. We report on
a boy with early onset dystonia, for whom work-up
performed in several institutions failed to reach a
diagnosis.
Methods
We performed homozygosity mapping in the patient by
using the Human Omni2.5 array (Illumina), and whole-
exome sequencing (IntegraGen), using the SureSelect V4
capture kit (Agilent) and the HighSeq2000 sequencer
(Illumina) [1].
For cell cultures work up, skin fibroblasts were main-
tained in DMEM (Life Technologies) with 10% FBS and
penicillin/streptomycin. Cells were either plated on glass
coverslips for immunofluorescence or pelleted for pro-
tein analysis. Cells were imaged using an Olympus FV-
1000 confocal microscope, and electron microscopy was
performed as described [2,3].
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For Protein extraction and immunoblotting, Cell pel-
lets were lysed in Protein Lysis Buffer. Proteins (20 μg)
were separated by SDS-PAGE and transferred to nitro-
cellulose. Membranes were blocked with blocking buffer
and incubated with primary or secondary antibodies di-
luted in the same buffer [3] (secondary Alexa-conjugates
antibodies: Life Technologies; HRP-conjugated anti-
bodies: Jackson ImmunoResearch).
Ethic statement
Written informed consent was obtained from the pa-
tient’s legal guardian(s) for gene analysis and publication
of this case report and any accompanying images. A
copy of the written consent is available for review by the
Editor-in-Chief of this journal.
Result and discussion
The boy was born after an uneventful pregnancy to
healthy Moroccan parents who are second-degree re-
lated (Figure 1A). Familial history was irrelevant. Motor
milestones were normal until the age of three, when the
boy began to fall frequently and to develop progressive
dystonia that first affected lower limbs and spread rap-
idly to upper limbs, trunk, and face. He lost ambulation
Figure 1 Familial pedigree and brain MRI of the patient. A. Familial pedigree. B. Sagittal 3DT1 gradient-echo image shows enlargement of
the vermian fissures, which demonstrated cerebellar atrophy (mainly anterior). Reformatted axial 3DT1 gradient-echo image shows small lentiform
nuclei compared to caudate nuclei volume. Slight enlargement of the lateral ventricles was also present. C. Sanger sequencing of TOR1AIP1 shows
a homozygous A to C variant at position 179,887,067 on chromosome 1 in the patient (V1). Both parents are heterozygous carriers (IV 1 and IV2).
D. The mutated glutamic acid (surrounded by blue lines) is conserved across a broad range of species.
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at the age of 5. Dystonia was permanent, exacerbated by
illness or stress, and by the age of 10 was completely
generalized and extremely painful. The child spent most
of the day and night crying and was unable to maintain
a sufficient level of food and liquid intake (Additional file
1: Video S1). Severe contractures of the Achilles tendons
and permanent feet deformations were noticed. Cerebellar
maneuvers on upper limbs were normal. There was no
ophthalmoplegia, ptosis, or pyramidal signs. Intelligence
appeared normal. Medications, including paracetamol, opi-
oids, benzodiazepines (diazepam, clonazepam, clobazam),
L-Dopa, phenobarbitone, levetiracetam, piracetam, vigaba-
trin, propanolol, trihexyphenidyl hydrochloride, dantrolene,
baclofen, carbamazepine, valproic acid, topiramate, chlor-
promazine, amytriptiline, tetrabenazine, 1,3,5-benzenetriol,
and magnesium sulfate, were tried unsuccessfully. The
child’s pain was temporally relieved by intravenous chlor-
promazine. Nabiximols led to a dramatic relief of pain and
dystonia, and allowed the patient to re-acquire the abil-
ity to swallow, sit, and perform some voluntary move-
ment (Additional file 2: Video S2). Attempts to wean the
patient off medication led to rapid recurrence of pain. At
the age of 14, a dilated cardiomyopathy was diagnosed,
and ejection fraction rapidly decreased leading to death at
the age of 17.
Prior to death, brain MRIs showed progressive global
cerebellar atrophy (Figure 1B). Monovoxel MR spectros-
copy of the left basal ganglia revealed a reduced NAA/
Cr ratio indicative of neuronal loss without iron accu-
mulation. Brain PET scans, electroencephalographic re-
cordings, somatosensory evoked potentials, audition and
fundus examination, electroneurography, liver and kid-
ney echographies were unremarkable. Muscle biopsy,
performed at the age of 6, revealed no abnormalities or
biochemical deficits. Glucose, proteins, lactate, blood cell
count, and neurotransmitters levels in the CSF were nor-
mal. Analyses for each of the following, performed at
least once, were normal: blood cell count, ASAT, ALAT,
CK, urea, creatinine, cholesterol, triglyceride, arterial lac-
tate and pyruvate levels, ceruloplasmin, cupremia and
cupruria, alpha fetoprotein, very long chain fatty acids
and long chain fatty acids, biopterin, urine creatine and
guanidinoacetate, amino acid (blood and urine) and organo
acid (urine) chromatography, high-resolution caryotype,
glucocerebrosidase, galactocerebrosidase, β-galactosidase,
α-N-acetylgalacosaminidase, aryl sulfatase A, hexosa-
minidase A and B, α-glucosaminidase, β-glucuronidase,
α-mannosidase, β-mannosidase, α-neuraminidase, acid
sphingomyelinidase mucopolysaccharidoses and oligo-
saccharidoses, and sialotransferrin. No acanthocytosis
was present on any of several blood smears.
No mutations were identified in DYT1, PANK2,
PLA2G6, SCA17, or APTX, genes known to be in-
volved in neurodegenerative diseases with cerebellar
atrophy and/or dystonia. Given consanguinity in the
family, we assumed a recessive mode of inheritance
and predicted the causative variant would fall in a re-
gion of homozygosity.
Homozygosity mapping revealed six homozygous re-
gions greater than 2 Mb. Whole exome sequencing pro-
duced 142 million reads, 98% of which could be aligned
to the targeted sequence. Mean coverage of the targeted
sequence was 77 fold. 56 687 SNVs and 7 265 indels
were called. Only nine homozygous variants with fre-
quency below 1% in internal (IntegraGen) and public da-
tabases (dbSNP 132; HapMap; 1,000 Genomes Project)
were filtered out of these. Sequencing in the patient and
in family members (primers available upon request) re-
duced the number of candidates to four genes, present
at the homozygous state in the patient, and at the
heterozygous state in the parents: ALMS1, B3GALT1,
ZNF804B, and TOR1AIP1.
The A>C missense variant (c.1448A>C) at position
179,887,067 on chromosome 1q25.1-1q25.3 in TOR1-
AIP1 (NM_015602), located in a 6.8-Mb homozygosity
region, resulted in replacement of a highly conserved
glutamic acid with alanine at amino acid 482 (GERP++
score 5.96; PhyloP score 2.285) (Figure 1C,D). Further-
more, pathogenicity predictions were deleterious in Align
GVGD, Polyphen-2, SIFT, and MutationTaster analyses.
On the contrary, the variants in ALMS1 (NM_015120;
c.2202T>A/p.S732R), B3GALT1 (c.192A>T/p.E64D, NM_
020981) and ZNF804B (c3118C>A/p.L1040I, NM_181646),
were predicted to be benign by at least three of the above-
mentioned programs. GERP++ and PhyloP scores were
lower for the ZNF804B variant (GERP++ score 4.15, PhyloP
score 1.467), and even negative for the ALMS1 and
B3GALT1 variants. There was thus a strong bioinformatic
convergence towards the pathogenic character of the
TOR1AIP1 variant only. In addition, the phenotype of this
patient was divergent from that of Alström syndrome
(OMIM #203800) patients who have mutations in ALMS1.
TOR1AIP1 encodes LAP1, a type II transmembrane pro-
tein. LAP1 interacts with torsinA (encoded by TOR1A
gene), which is mutated in autosomal dominant dystonia
(DYT1; OMIM #12810) [4]. The amino acid mutated in
our patient is located in the luminal domain, which inter-
acts with torsinA. This domain is common to the three iso-
forms and has significant homology with LULL1, another
protein that interacts with torsinA. This variant was not ob-
served in any of 100 ethnically matched controls and was
absent from >6500 exomes at the Exome Variant Server.
To gain insight into the pathogenicity of the TOR1-
AIP1 mutation, we evaluated primary skin fibroblasts
from the patient. By western blot, a strong reduction in
the expression of LAP1 isoforms was observed relative
to control cells (Figure 2A). Immunolabeling revealed a
significant reduction in LAP1 staining in the nuclear
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envelope of patient cells (Figure 2B). Although the endo-
plasmic reticulum was generally faintly stained, some
areas showed accumulation of LAP1 (Figure 2B), indicat-
ing mislocalization of the mutated LAP1. No defects in
A-type or B-type lamins, SUN1, SUN2, or nesprin-1 or 2
protein localization were observed (data not shown). Simi-
larly, no blebs [4] in nuclear envelopes were observed by
electron microscopy in patient cells (Figure 2C). TorsinA
is not normally expressed in fibroblasts, so we were not
able to determine if this protein was mislocalized.
We have searched TOR1AIP1 mutation in 10 additional
patients with dystonia during childhood: Five with primary
dystonia associated with cerebellar atrophy and 5 with pri-
mary cerebellar ataxia with progressive cerebellar atrophy
and severe dystonia. We did not find mutations, which
seems to indicate that TOR1AIP1 mutation is not a com-
mon cause of dystonia of unknown origin.
To our knowledge, cerebellar atrophy, dystonia, and
dilated cardiomyopathy are very rarely associated, except
in some mitochondrial disease or organic acidemia. Our
patient did not suffer from organic acidemia and mito-
chondrial disorders were unlikely given normal blood
and CSF lactate levels, NMR spectroscopy, and muscular
biopsy. Cerebellar atrophy and dystonia are observed
in neurodegenerative diseases, such as Wilson disease,
acanthocytosis, gangliosidosis [5], and Niemann Pick
type C [6] and in some cases of spinocerebellar ataxias,
particularly SCA17 [7]. These were ruled out in the
patient. TUBB4A mutations have been recently involved
in patients with dystonia, cerebellar and basal ganglia
Figure 2 Sub-expression and mislocalization of LAP1. A. Three bands were observed using anti-LAP1 antibody in control fibroblasts. Fibroblasts
from the patient had significantly less of the larger isoforms, whereas the expression of the shorter isoform was less affected (LAP1 antibodies: courtesy
of Dr. W.T. Dauer, anti-GAPDH: Santa Cruz Biotechnology; Olympus FV-1000 confocal microscope). B. Fibroblasts from patient show a strong reduction
or total absence of LAP1 at the nuclear envelope. A faint staining for LAP1 was observed at the ER (stained with calnexin antibodies, Santa Cruz
Biotechnology; secondary Alexa-conjugates antibodies, Life Technologies; HRP-conjugated antibodies: Jackson ImmunoResearch), and strong staining
was observed in some regions (see magnification in the inset). Scale bar: 10 μm. C. Electron micrograph of patient fibroblast did not reveal alterations
at the nuclear envelope. Scale bar: 5 μm; inset: 500 nm. Imaging as described before [3].
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atrophy and hypomyelinating leukodystrophies (HABC
syndrome) [8]. In addition to the absence of white mat-
ter abnormalities in our case, exome analysis ruled out
TUBB4A mutations. In the clinical work up, other
causes of dystonia (such as DYT1 and PANK2 mutation)
or cerebellar atrophy (such as PLA2G6 mutation) were
also ruled out. Much older patients who have presented
with the association of a less severe dystonia and a cere-
bellar atrophy have been described [9]. Extreme painfull
dystonia was one of the primary clinical features ob-
served when we first evaluated the child at the age of 11.
Absence of effect of any usual oral medications tried by
us and others, and the dramatic improvement upon ad-
ministration of nabiximols, a cannabinoid derived from
cannabis plant [10], remains very enigmatic but as been
reported in adults with central pain and paroxysmal
dystonia [11].
LAP1, encoded by TOR1AIP1, induces the ATPase ac-
tivity of torsinA [12], the protein mutated in DYT1, an
autosomal dominant dystonia with purely neurological
phenotype. LAP1 is the only protein with such function
at the nuclear envelope described so far, and hence its
mislocalization likely leads to a dramatic loss of function
of torsinA and probably of other torsin family proteins
[12]. Mice lacking LAP1 have abnormal nuclear mem-
branes that form blebs visible by electron microscopy in
all cell types [4]. In mice lacking torsinA, blebs are only
present in neurons, probably because of the high level of
torsinB in non-neuronal cells [13]. Such blebs were not
observed in patient’s fibroblasts. The mutated LAP1
expressed by the patient may retain some functions re-
quired for the structure of the nuclear envelope. Our
case appears much more severe than DYT1, not only
because of the severity of dystonia itself, but because of
the cardiac involvement, similar to the phenotype of
Tor1a
∆E/∆E mice [4] and with disorders of nuclear mem-
brane such as laminopathies [3]. Recently, cardiomyop-
athy has been demonstrated in a tissue-specific mutant
lacking LAP1 [14].
One Turkish family with a homozygous nonsense mu-
tation was recently reported [15]. Interestingly, affected
patients also present with a cardiomyopathy, although
less severe than that observed in our patient, and associ-
ated with a limb-girdle muscular dystrophy.
Conclusions
The present observation is unique, and, therefore, it can-
not be completely ruled out that the phenotype is not
related to a mutation in a region not covered by exome
sequencing. However, we believe that the association
between the previously unreported phenotype of the
patient and the mutation is very likely. First, clinical
evaluations failed to identify another likely cause. Second,
the mutation affects a highly conserved amino acid, is
predicted to be pathogenic, is absent in 100 ethnically
matched controls and in >6500 exomes, and affects a pro-
tein that interacts with a protein involved in dystonia.
Third, the patient phenotype correlates with that of mice
lacking LAP1 [14], and functional explorations of patient
cells revealed reduced LAP1 expression and mislocaliza-
tion. It is known that adequate localization of LAP1 is
crucial for its function [12]. Finally, another family has
been reported with nonsense mutation leading to cardio-
myopathy [15]. For these different reasons, we believe that
sequencing of TOR1AIP1 should be performed in patients
with similar peculiar phenotypic associations.
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